Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SENL_1904A
- Development stage
- Phase 1
- Lead developer
- Senlang Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
SENL_1904A is a CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy developed by SenlangBio. The therapy involves modifying a patient's own T cells to express a receptor specific for the CD19 antigen found on the surface of B cells, thereby redirecting the immune system to recognize and kill malignant B cells, typically used for B cell malignancies such as acute lymphoblastic leukemia and non-Hodgkin’s lymphoma[5][3].
- Other names
- Senl 1904ASenl1904ASenl-1904ASenl_1904A CD19 CAR-T cell therapy
02
Targets
Beyond the preview
Go deeper on SENL_1904A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SENL_1904A.